Recently Featured

Nektar Reports One-Year Eczema Treatment Success with Rezpeg; Pfizer Concludes Malnutrition Study

February 13, 2026
Nektar Therapeutics has announced that its investigational drug rezpegaldesleukin, or rezpeg, has demonstrated sustained efficacy in treating eczema over a one-year follow-up period. The data indicates that patients experienced not only maintenance but also a deepening of skin clearances, suggesting a significant advancement in long-term management of the condition. This outcome positions Nektar favorably within…

Fujifilm Biotechnologies completes £400M expansion of UK antibody production facility

February 13, 2026
Fujifilm Biotechnologies has officially inaugurated its expanded site in Teesside, UK, marking the completion of a £400 million (approximately $546 million) investment that has been in development since late 2021. This facility is now recognized as the largest single-use biopharmaceutical contract development and manufacturing organization (CDMO) in the United Kingdom, positioning Fujifilm as a key…

Calla Lily Clinical Care & Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform

February 12, 2026
Calla Lily Clinical Care and Merck have entered a strategic collaboration to support the continued development of Callavid®, a novel platform for intravaginal drug delivery. This partnership marks the first industry collaboration for the Callavid technology, which aims to address significant challenges in the self-administration of vaginal therapeutics. The Callavid device is designed to mitigate…

Eliquis Sales to Fall as European Patent Expiry Nears

February 12, 2026
Global sales of Bristol Myers Squibb’s (BMS) and Pfizer’s drug Eliquis (apixaban) are projected to decline by 15.2% in 2026 due to the loss of its European market exclusivity on May 19, 2026, according to GlobalData, a leading intelligence and productivity platform. According to GlobalData’s Pharmaceutical Intelligence Center Sales and Forecast Database, the BMS-Pfizer alliance…

Ongoing Cases